Evidence map›Paper›PMID 31938376›Full record

ArticleInternational journal of clinical and experimental pathology2018

Identification of lncRNAs via microarray analysis for predicting HER2-negative breast cancer response to neoadjuvant chemotherapy.

Dengjie Ouyang, Juan Su, Peng Huang, Moyun Li, Qianying Li, Piao Zhao, Qitong Chen, Qiongyan Zou, Xueping Feng, Ke Qian and 2 more

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Dengjie OuyangDepartment of Breast and Thyroid Surgery, The Second Xiangya Hospital, Central South University China.
Juan SuDepartment of Breast and Thyroid Surgery, The Second Xiangya Hospital, Central South University China.
Peng HuangDepartment of General Surgery, Xiangya Hospital, Central South University China.
Moyun LiDepartment of Breast and Thyroid Surgery, The Second Xiangya Hospital, Central South University China.
Qianying LiDepartment of Breast and Thyroid Surgery, The Second Xiangya Hospital, Central South University China.
Piao ZhaoDepartment of Breast and Thyroid Surgery, The Second Xiangya Hospital, Central South University China.
Qitong ChenDepartment of Breast and Thyroid Surgery, The Second Xiangya Hospital, Central South University China.
Qiongyan ZouDepartment of Breast and Thyroid Surgery, The Second Xiangya Hospital, Central South University China.
Xueping FengInstitute of Medical Science, Xiangya Hospital, Central South University China.
Ke QianDepartment of Breast and Thyroid Surgery, The Second Xiangya Hospital, Central South University China.
Lun LiDepartment of Breast and Thyroid Surgery, The Second Xiangya Hospital, Central South University China.
Wenjun YiDepartment of Breast and Thyroid Surgery, The Second Xiangya Hospital, Central South University China.
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mortality is high in patients with locally advanced HER2-negative breast cancer, especially those with residual tumor after neoadjuvant chemotherapy (NAC). Tissue-specific long non-coding RNAs (lncRNAs) are responsible for specific breast cancer subtypes. To identify the lncRNAs involved in residual cancer tissues (RCTs) and to evaluate their potential for predicting HER2-negative breast cancer response to NAC, we used three paired tissues to compare differences in gene expression between RCTs and remittent tissues (RTs) after NAC in human HER2-negative breast cancer. Subsequently, we detected expression of the top ten up-regulated and down-regulated lncRNAs in 11 paired tissues via quantitative RT-PCR analysis. Finally, we explored the potential function of these dysregulated lncRNAs through bioinformatics analysis. Our results indicate that 1348 mRNAs and 183 lncRNAs were differentially expressed in RCTs compared with RTs, and the expression levels of four novel lncRNAs (DSCAM-AS1, LINC01508, lnc-MGST1-2 and lnc-BTG2-2) were in agreement with the microarray analysis results. Furthermore, we found that the expression level of LINC01508 was significantly related to poor prognosis, suggesting that LINC01508 is a potential biomarker for predicting breast cancer response to NAC, which might be helpful in exploring potential diagnostic factors and therapeutic targets for chemo-resistant HER2-negative breast cancer.

Indexed as

chemo-resistancegene expression microarrayHER2-negative breast cancerlong non-coding RNAs/lncRNAsneoadjuvant chemotherapy

Identifiers

PMID31938376
PMCPMC6958288
OpenAlexW3005191365

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.